



MILANO 4-5 OTTOBRE 2024

**CHIRURGIA BARIATRICA
PER IMMAGINI
UNA DIVERSA PROSPETTIVA**

PRESIDENTE ALESSANDRO GIOVANELLI

STUDIO PRE-OPERATORIO

L'importanza di una Endoscopia mirata

Vito Annese

*Gastroenterologia IRCCS Pol. S. Donato
Università Vita e Salute, S. Raffaele*

Disclosure



I have no conflict of interest to disclose for this lecture

Pre-Op Endoscopy - Background

- The rationale for performing an EGD before bariatric surgery is to detect and/or treat lesions that might potentially affect the type of surgery performed, cause complications in the immediate postoperative period, or result in symptoms after surgery
- However, the need for EGD before bariatric surgery is **controversial**.








Most common pre-op endoscopy findings in obese



■ Hitala Hernia ■ Esophagitis ■ Gastric ulcer ■ Barrett ■ Duodenal ulcer ■ Gastric cancer ■ Esophageal K

Bennett S et al. Surg Obes Rel Dis 2016;12:1116-1125 (48 studies, 61,421 patients)

Most common pre-op pathology findings in obese








■ Helicobacter ■ Atrophic gastritis ■ Intestinal metaplasia ■ GIST

Wang S et al. Obes Surg 2021;31:337-42 (59 studies, 32,789 patients)

DISEASES OF THE ESOPHAGUS

Guideline

Gastro-esophageal diagnostic workup before bariatric surgery or endoscopic treatment for obesity: position statement of the International Society of Diseases of the Esophagus

Pierfrancesco Visaggi, ^{1,2} Matteo Ghisa, ³ Brigida Barberio,⁴ Philip W. Chiu,⁵ Ryu Ishihara,⁶ Geoffrey P. Kohn,^{7,8} Sergey Morozov,⁹ Sarah K. Thompson, ¹⁰ Ian Wong, ⁵ Cesare Hassan,^{11,12} Edoardo Vincenzo Savarino ^{4,13}



Statement 1

- Preoperative esophagogastroduodenoscopy should be considered in all patients planning to undergo bariatric surgery.

Conditional Recommendation – Low Quality Evidence (Agree=90%)



Statement 1

- In a meta-analysis on 594 patients, an association has been demonstrated between obesity and **reflux esophagitis** (OR=2.23, 95%CI:1.6 - 3.1, P=0.000), **erosive gastritis, gastric and duodenal ulcers** (OR=1.40, 95% CI:1.14–1.7, P=0.001)[1]
- In another meta-analysis, the pooled adjusted OR of **esophageal adenocarcinoma** for BMI of 25 or greater was 2.02 (95% CI:1.5–2.7; P=0.001), with a trend toward a dose–response relationship [2]
- A meta-analysis on 13,434 patients undergoing endoscopy prior to bariatric surgery, found a prevalence of **Barrett's esophagus** of 0.9% (95% CI:0.7%–1.3%; P<0.001)[3]

1.Kim HJ, et al J Gastroenterol Hepatol 2007;22(4):477–81.

2.Hampel H, et al. Ann Intern Med 2005;143(3):199–211.

3.Qumseya B, et al. Endoscopy 2020;52(7):537–47.



Statement 1

- A change in surgical management of candidates for bariatric surgery following EGDS has been reported in the range of 3.9% (95% CI: 3%–4.8%) to 20.6% (95% CI: 14.5%–28.2%)
- The proportion of medical management changes ranged from 0% to 70.2% in single studies and was mainly due to Helicobacter pylori (HP) eradication (76.4%) and medical therapy for gastritis or GERD (23.5%)

Statement 2



- Identification and subsequent repair of HH larger than 2 cm may improve outcomes in patients undergoing bariatric procedures.
- *Conditional Recommendation—Low Quality Evidence.*



Statement 2

- HH may be present in nearly 40% of morbidly obese patients [1]
- A recent meta-analysis investigated the effects of concomitant LSG and HHR in patients with GERD. From the pooled analysis of 18 randomized (n=1) and nonrandomized (n=17) studies including 937 patients, the authors found that concomitant LSG and HHR had a **positive effect on weight loss, erosive esophagitis** (OR=0.12), and improvement of **GERD symptoms** (OR=0.20). [2]
- In addition, the OR for remission of GERD symptoms was significantly higher in patients undergoing LSG+HHR compared to LSG without HHR (OR=2.97; 95%CI: 1.8–4.9, P<0.0001).



Statement 2

- In contrast, another meta-analysis on 838 patients found that although HHR significantly prolonged the procedure time of LSG, there was **no differences** in terms of **GERD improvement** in patients undergoing HHR+LSG or LSG alone.[1]
- In a RCT, 100 obese patients with HH who were scheduled for bariatric surgery were randomized to LSG with crural repair or LSG alone. The authors found that LSG with or without HHR had **comparable outcomes** in terms of postoperative reflux symptoms.[2]
- Evidence on a possible superiority of LSG+HHR compared to LSG alone is contradictory. Further randomized studies are needed to increase the quality of available evidence. However, current evidence suggests the need of identifying a HH and treating it accordingly.

1. Małczak P, et al. Pol Przegl Chir 2021;93(5):1–6.

2. Snyder B, Surg Obes Relat Dis 2016;12(9):1681–8.

Statement 7



- No recommendation can be made on the screening for *Helicobacter pylori* infection in patients planning bariatric procedures based on currently available evidence.
- *Agree:81.8%. No recommendation*



Statement 7

- Prevalence estimates of HP infection in obese patients undergoing bariatric procedures are heterogeneous, with meta-analytic studies showing prevalence rates ranging from 0.13% to 49%. Similarly, the impact of HP infection on surgical outcomes is unclear.][1]
- In a meta-analysis on 255,435 patients undergoing bariatric procedures, HP infection was associated with a **10-fold increase** in marginal **ulcers** formation following RYGB compared to HP-negative patients. However, the rates of bleeding, leak, hospital length of stay was the same [2]
- Another meta-analysis found that there was **no difference in the incidence of post operative complications** in HP-positive patients undergoing pre-operative HP eradication therapy compared to HP-negative patients [1]

1. Smelt HJM, et al. Surg Obes Relat Dis 2018;14(10):1645–57.
2. Mocanu V, et al. Obes Surg 2018;28(2):567–73.

Impact of pre-op Endoscopy

The need for EGD before bariatric surgery is controversial.



A retrospective study design
January 2012 to July 2020



Total of 461 patients who underwent EGD before bariatric surgery

The EGD findings were classified into four groups



Group 1: Normal



Group 2: Abnormal findings did not require a change in surgical plan



Group 3: Abnormal findings require a change or delay in surgical management



Group 4: Contraindications

Demographic data



Mean age was 35.1 ± 11.2 years

Mean BMI was 47.7 ± 8.7 kg/m²

The prevalence of endoscopic findings



42.5%



35.6%



21.9%



0%




Male gender



NSAID use

Significantly associated

Abnormal endoscopic findings that required a change in the surgical plan or caused a delay in surgical treatment.



A nomogram for the patients age ≥ 40 years old

Conclusions

A high prevalence of abnormal endoscopic findings in preoperative EGD evaluations in Thai bariatric patients.

Preoperative EGD should be considered in all patients undergoing bariatric surgery to find the UGI abnormalities that might require a change in the surgical decision plan.



A survey on pre-op Endoscopy

- A retrospective chart review of 885 patients who underwent primary bariatric surgery
- One or more abnormal EGD findings were observed in 83.2% of patients
- More than half of our patients (54.7%) presented with history of heartburn, reflux, or GERD.
- EGD findings demonstrated a hernia in 43.1% of patients [(Type I: 40.6%; Type II: 0.5%; Type III: 2.1%)].
- Among patients who were biopsied, other findings included gastritis (32.4%), esophagitis (8.0%), eosinophilic esophagitis (4.7%), or duodenitis (2.7%)





A survey on pre-op Endoscopy


- Among patients who were biopsied, other findings included gastritis (32.4%), esophagitis (8.0%), eosinophilic esophagitis (4.7%), or duodenitis (2.7%).
- We found ulcers in 6.7% of patients. Pathology was consistent with H. pylori in 9.8% of biopsies taken and consistent with BE in 2.7%.
- Following routine p-EGD, 11.2% of patients were placed on PPI and 8.3% were recommended to stop NSAIDs.

Gastric sleeve & Barrett

Journal Pre-proof

Risk of De Novo Barrett's Esophagus (BE) Post Sleeve Gastrectomy (SG): A Systematic Review and Meta-analysis of Studies with Long Term Follow up

- 19 studies with 2046 patients 
- Mean  → 2 to 11.4 years
- Pooled rate of de novo BE → 5.6%



Reflux Symptoms

Erosive Esophagitis

Hiatal Hernia


 PPI Use

| | Pre SG | Post SG |
|---------------------|--------|---------|
| Reflux Symptoms | 14.6% | 48% |
| Erosive Esophagitis | 7.7% | 33.4% |
| Hiatal Hernia | 14.8% | 32.1% |
| PPI Use | 13.5% | 54.6% |

Clinical Gastroenterology
and Hepatology

Gastric sleeve & Barrett

Post Op De Novo Barrett's Esophagus



How reliable is pre-sleeve endoscopy to characterize pathological features?



- Cross-sectional study examined 102 patients who underwent vertical sleeve gastrectomy from January 2023 to November 2023.
- The negative predictive value of preoperative esophago-gastroduodenoscopy for detecting H. pylori infection, gastritis, metaplasia and atrophy were 95 %, 79 %, 93 %, and 98 %, respectively.
- Moderate gastritis and focal metaplasia were significantly underdiagnosed preoperatively ($p < 0.001$).
- H. pylori infection and focal metaplasia were significantly more prevalent in females after surgery ($p < 0.001$).
- H. pylori infection and gastritis were positively correlated with increased postoperative gastroesophageal reflux disease symptoms ($p < 0.001$).

Frequency of Clinically Significant Findings in the Surgical Pathology Specimen Following Laparoscopic Sleeve Gastrectomy and Concordance with Preoperative Endoscopy



- Three hundred seventy-three patients had preoperative endoscopy and surgical pathology results available.
- 20/373 (5.4%) patients had potentially significant postoperative pathology, including intestinal metaplasia, autoimmune metaplastic atrophic gastritis (AMAG), gastrointestinal stromal tumors, and/or gastric cancer.
- The overall incidence of AMAG in the entire cohort was 2.3%. Preoperative gastric biopsies (to include gastric body) identified AMAG in nearly 1/2 of patients.
- Patients with clinically significant postoperative pathology results had a median [interquartile range] of 3 [3–5] tissue blocks examined as compared to 3 [1–3] for the remainder of the cohort ($p < 0.001$).
- We recommend wider sampling in preoperative endoscopy (body and antrum)

Pre-Op EGDS – High cost for low yield



- 31 retrospective observational studies (EGD=13,837)
- Meta-analysis found 3.9% of EGDs resulted in a change in operative management
- This proportion decreased to 0.3% after sensitivity analysis, as detection of hiatal hernia comprised 85.7% of findings that changed operative management.
- Half of the 7.5% of cases that resulted in surgical delay involved endoscopic detection of H. pylori.
- Gastric pathology was detected in a significantly greater proportion of symptomatic patients (65.0%) than in asymptomatic patients (34.1%; $P<0.001$).

Pre-Op EGDS – High cost for low yield



TABLE 2. Absolute Value [% of Total EGDS (n = 13,837)] of Operative Change or Delay by Abnormality

| Absolute Value and Corresponding Percentage of Total EGDS [n = 13,837] of Operative Delay or Change by Abnormality | Operative Delay [n (%)] | Operative Change [n (%)] |
|---|--------------------------------|---------------------------------|
| Hiatal hernia | 0 | 694 (5) |
| Esophagitis | 170 (1.2) | 17 (0.12) |
| Gastritis | 299 (2.2) | 0 |
| Duodenitis | 77 (0.6) | 0 |
| Gastric ulcer | 139 (1.0) | 5 (0.04) |
| Gastric polyp | 19 (0.14) | 1 (<0.01) |
| Duodenal polyp | 1 (<0.01) | 0 |
| Barrett's esophagus | 10 (0.07) | 7 (0.05) |
| Cancer | 0 | 12 (0.09) |

EGD indicates esophagogastroduodenoscopy.



Pre-Op EGDS – High cost for low yield

- The cost of routine EGD to identify any abnormality that led to a change in type of bariatric operation was **\$281,230** and **\$766,352** when controversial findings were included versus excluded, respectively.
- Cost of routine EGD to identify a **malignancy** was **\$2,554,506**
- **Estimated cost of EGD was \$2215**
- **Estimated cost including histology SSN is 140€**
- **Cost included in bariatric package ± 230 €**



Take home messages

- The performance of an upper endoscopy in a patient with reflux symptoms, dysphagia, and/or dyspepsia has been covered in multiple guidelines and is equally relevant in the preoperative patient
- RYGB and DS/BPD render the distal stomach and/or duodenum inaccessible by a standard upper endoscope, the threshold for performing a preoperative endoscopic evaluation of the upper-GI tract is lower than for other surgeries
- The relative low cost and possible legal implication warrant the EGD in all patients before bariatric procedures

